Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

Inclusion criteria: * Subjects aged ≥18. * Body temperature \< 37.3 ° C confirmed by clinical examination before enrollment . * CD4+ count is less than 500/ul and more than 50/ul . * Female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. * Able and willing to complete the entire study plan during the study follow-up period. * Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. Exclusion criteria for the first dose: * Being allergic to any component of vaccines (including excipients) . * Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). * Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome. * Pregnant and lactating women. * The subjects are suffering from an acute illness; Or thrombocytopenia patients with platelet count \< 20×10\^9/L within three days before inoculation, that is, patients at high risk of spontaneous bleeding. * Acute HIV infection and opportunistic infection. * Subjects with co-opportunistic infections who did not receive antiviral therapy. * Subjects with CD4+ count less than 50/ul who have not received antiviral therapy. * HIV-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * Patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. * Other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies. Exclusion criteria for the second dose: * Subjects who had vaccine-related adverse reactions after the first dose. * Having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction. * Having any adverse nervous system reaction after the first dose. * During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks. * Subjects with severe immunodeficiency (CD4+ count less than 50/ul). * Acute HIV infection and opportunistic infection. * Subjects with co-opportunistic infections who did not receive antiviral therapy. * HIV-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * Other reasons for exclusion considered by the investigator.